Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition
|
results for the quarter ended March 31, 2017. A copy of the press
release is attached to this current report on Form 8-K as Exhibit
99.1.
Form 8-K shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934 (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits>
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of Lexicon Pharmaceuticals, Inc. dated
May 2, 2017 |
|
About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company’s other programs include LX1033, LX2931 and LX7101. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Recent Trading Information
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) closed its last trading session up +0.03 at 15.69 with 436,649 shares trading hands.